Table 4

Studies of quantitative real-time myocardial contrast echocardiography during adenosine stress in patients with known or suspected coronary artery disease

FeatureKorosoglou et al7Malm et al5Kowatsch et al4Osorio et al6Vogel et al10Present study
Contrast agentSonoVue*Optison†PESDAPESDASonoVue*Definity‡
MCE, No of patients475354714879
Reference testSPECT and coronary angiographyCoronary angiographyCoronary angiographyCoronary angiographyCoronary angiographySPECT
Prevalence of CAD (%)§624446357748
Level of analysis and data presentationSegmental, territorial and patientTerritorialTerritorialTerritorialTerritorialSegmental,¶ territorial and patient
Diagnostic accuracy of β reserve
    Sensitivity (%)797788808782
    Specificity (%)757272978366
Diagnostic accuracy of MBF reserve
    Sensitivity (%)807776848973
    Specificity (%)786967879272
  • *SonoVue (sulfur hexafluoride microbubbles); Bracco Diagnostics; Milan, Italy.

  • †Optison (perflutren protein-type A microspheres); GE Healthcare, Princeton, NJ, USA.

  • ‡Definity (perflutren lipid microspheres); Lantheus Medical Imaging, Inc, North Billerica, MA, USA.

  • §Prevalence of disease was calculated on the number of patients reported to have the disease on the basis of the reference test.

  • ¶Data presented on segmental level in this table.

  • AUC, area under the receiver operating characteristic curve; β, myocardial blood flow velocity; CAD, coronary artery disease; MBF, myocardial blood flow; MCE, myocardial contrast echocardiography; NA, not available; PESDA, perfluorocarbon-exposed sonicated dextrose albumin; SPECT, single-photon emission computed tomography.